Currently, there are 585.75M common shares owned by the public and among those 574.31M shares have been available to trade.
The company’s stock has a 5-day price change of 8.05% and 5.13% over the past three months. EW shares are trading 3.04% year to date (YTD), with the 12-month market performance down to -13.33% lower. It has a 12-month low price of $58.93 and touched a high of $95.25 over the same period. EW has an average intraday trading volume of 4.77 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.95%, 6.95%, and 8.10% respectively.
Institutional ownership of Edwards Lifesciences Corp (NYSE: EW) shares accounts for 87.35% of the company’s 585.75M shares outstanding.
It has a market capitalization of $44.68B and a beta (3y monthly) value of 1.12. The stock’s trailing 12-month PE ratio is 30.81, while the earnings-per-share (ttm) stands at $2.48. The company has a PEG of 3.60 and a Quick Ratio of 3.45 with the debt-to-equity ratio at 0.06. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.17% over the week and 3.42% over the month.
Earnings per share for the fiscal year are expected to increase by 1.59%, and 11.52% over the next financial year. EPS should grow at an annualized rate of 8.55% over the next five years, compared to -2.36% over the past 5-year period.
Looking at the support for the EW, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on April 24, 2025, with the firm’s price target at $80. Stifel coverage for the Edwards Lifesciences Corp (EW) stock in a research note released on January 30, 2025 offered a Buy rating with a price target of $90. Morgan Stanley on their part issued Equal-Weight rating on October 11, 2024.
